Learning a second language improves brain structures in MS
The study in brief
Learning a second language is linked to changes in brain connections, known as neuroplasticity, and also leads to improvements in general cognitive skills, not just those associated with language. This has not been studied in MS, so researchers designed a pilot study to see whether people with MS gained similar benefits from learning a new language.
Researchers in Austria recruited 11 people with early stage relapsing remitting MS and 12 people who did not have MS for comparison. Both groups took part in an eight-week English language course. MRI scans before and after the course were used to measure changes in the volume of grey matter in the brain. Participants also completed questionnaires to assess quality of life relating to physical and mental health and completed tests to measure their improvement in speaking and understanding English.
Both groups improved their proficiency in English. Mental health quality of life improved in the MS group. MRI scans taken before the course showed a significantly lower grey matter volume in several regions of the brain in people with MS when compared to those who did not have MS. After completing the course, the scans showed an increase in grey matter volume in areas of the brain responsible for short-term memory, learning and environment recognition.
The increase in grey matter volume seen in this study provides some evidence of neuroplasticity, the brain’s ability to make new connections and rewire itself. The researchers suggested that improved mental health for MS participants showed that taking part in the language course was a positive experience and enhanced their confidence in dealing with challenges.
The small number of people in this study means that the results should be interpreted with caution; a larger study will be needed to confirm the findings. Further studies could also investigate whether learning a second language or another skill might protect or improve broader cognitive skills in MS, such as memory and concentration.
The study in more detail
Background
Research has shown that learning a second language is linked to changes in brain connections, known as neuroplasticity, in parts of the brain which are related to language learning. Learning a second language also leads to improvements in general cognitive skills, not just those associated with language. As this has not previously been studied in MS, researchers designed a pilot study to see whether people with MS gained similar benefits from learning a new language.
How this study was carried out
Researchers in Austria recruited 11 people with early stage relapsing remitting MS and 12 people who did not have MS for comparison. Participants attended an eight-week English language course which consisted of three hours each week in a classroom setting, and completed extra tasks, such as learning vocabulary, at home between classes.
MRI scans were used to measure the volume of grey matter in the brain. Scans were carried out before and after the language course. Participants also completed questionnaires to assess quality of life relating to physical and mental health and completed tests to measure their improvement in speaking and understanding English.
What was found?
Before the course, the level of English proficiency was the same for the two groups, those with MS and those who did not have MS. After completing the course, both groups had increased English proficiency with significant improvements in listening comprehension, speaking fluency and vocabulary knowledge in all participants.
Before the course, quality of life for physical health was similar in both groups, but mental health quality of life was significantly lower in the MS group. After the course, physical health was unchanged for both groups, but scores for mental health were significantly improved in the MS group.
MRI scans taken before the course showed a significantly lower grey matter volume in several regions of the brain in people with MS when compared to those who did not have MS. However, after completing the course, the scans showed an increase in grey matter volume in areas of the brain responsible for short-term memory, learning and environment recognition.
Further analyses also showed that, in the MS group, increases in grey matter volume in specific areas of the brain were associated with a gain in vocabulary knowledge.
What does it mean?
The increase in grey matter volume seen in this study provides some evidence of neuroplasticity, the brain’s ability to make new connections and rewire itself. The researchers suggested that improved mental health for MS participants showed that taking part in the language course was a positive experience and enhanced their confidence in dealing with challenges.
The small number of people in this study means that the results should be interpreted with caution; a larger study will be needed to confirm the findings. It would also be interesting to see whether the increase in grey matter volume is maintained beyond the end of the language course and whether similar improvements are seen in people who have had MS for a longer time. Further studies could also investigate whether learning a second language or another skill might protect or improve broader cognitive skills in MS, such as memory and concentration.
Ehling R, et al.
Second language learning induces grey matter volume increase in people with multiple sclerosis.
Journal PLoS One. 2019;14(12):e0226525.
Read the full study
Find out more about brain connections and neuroplasticity
Brain tissue is divided into two types: white matter and grey matter. White matter is mostly made up of nerve axons, insulated by a coating of myelin, which gives this tissue its white appearance. Grey matter is largely made up of the bodies of nerve cells and the millions of connections between them.
During the course of MS, both white and grey matter are affected. The immune system attacks the myelin coating of nerve axons in white matter; over time nerve cells in the grey matter die and connections between cells are lost, leading to a decrease in grey matter volume (also known as brain atrophy). Loss of grey matter volume is used as marker for MS progression and is associated with increased disability and cognitive problems.
Learning a new skill, such as acquiring a second language, involves establishing new connections between nerve cells, which can be detected as an increase in grey matter volume. This ability of the brain to adapt and rewire is known as neuroplasticity and is the principle underlying rehabilitation therapies in MS; by practising something repeatedly, you encourage your brain to compensate for loss of nerve cells and connections by finding new routes around areas of damage.
Fancy trying it yourself? You can learn new languages using free online resources such as Duolingo or Memrise. Both offer a wide range of languages, you could really challenge yourself by tackling Klingon or High Valyrian!
Browse more from the latest research
Causes of MS
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MA.
Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.
Trends Mol Med. 2020 Mar;26(3):296-310. doi: 10.1016/j.molmed.2019.11.003. Epub 2019 Dec 17. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Disease modifying drugs
van Eijndhoven E, Brauer M, Kee R, MacEwan J, Mucha L, Wong SL, Durand A, Shafrin J.
Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.
J Med Econ. 2020 Jan 21:1-10. doi: 10.1080/13696998.2019.1711100. [Epub ahead of print]
Summary(link is external)
Mäurer M, Tiel-Wilck K, Oehm E, Richter N, Springer M, Oschmann P, Manzel A, Hieke-Schulz S, Zingler V, Kandenwein JA, Ziemssen T, Linker RA.
Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis.
Ther Adv Neurol Disord. 2019 Dec 19;12:1756286419892077. doi: 10.1177/1756286419892077. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Foley J, Carrillo-Infante C, Smith J, Evans K, Ho PR, Lee L, Kasliwal R, Stangel M, Vermersch P, Hutchinson M, Marinelli F, Smirnakis K; TYGRIS investigators..
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis.
Mult Scler Relat Disord. 2019 Nov 21;39:101863. doi: 10.1016/j.msard.2019.101863. [Epub ahead of print]
Summary(link is external)
Spelman T, Freilich J, Anell B, Wong SL, Hillert J.
Patients with High-Disease-Activity Relapsing-Remitting Multiple Sclerosis in Real-World Clinical Practice: A Population-Based Study in Sweden.
Clin Ther. 2019 Dec 31. pii: S0149-2918(19)30587-9. doi: 10.1016/j.clinthera.2019.11.018. [Epub ahead of print]
Summary(link is external)
Paolicelli D, Manni A, Iaffaldano A, Trojano M.
Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis.
CNS Drugs. 2020 Jan;34(1):65-92. doi: 10.1007/s40263-019-00691-7. Review.
Summary(link is external)
Buron MD, Magyari M, Chalmer TA, Sørensen PS, Sellebjerg F.
Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β.
Mult Scler Relat Disord. 2019 Dec 16;39:101894. doi: 10.1016/j.msard.2019.101894. [Epub ahead of print]
Summary(link is external)
Nørgaard TL, Andersen CU, Hilt C, Andersen CU.
Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod.
Basic Clin Pharmacol Toxicol. 2019 Dec 26. doi: 10.1111/bcpt.13381. [Epub ahead of print]
Summary(link is external)
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Cornelissen C, Ettle B; PANGAEA Study Group..
Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab.
Mult Scler Relat Disord. 2019 Dec 13;39:101893. doi: 10.1016/j.msard.2019.101893. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Mustonen T BM, Rauma I MD, Hartikainen P MD, PhD, Krüger J MD, PhD, Niiranen M MD, Selander T M.Sc, Simula S MD, PhD, Anne M R MD, PhD, Kuusisto H MD, PhD.
Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.
Mult Scler Relat Disord. 2019 Nov 5;38:101498. doi: 10.1016/j.msard.2019.101498. [Epub ahead of print]
Summary(link is external)
Freedman MS, Comi G, Coyle PK, Aldridge J, Chen L, Marhardt K, Kappos L.
No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a.
Mult Scler Relat Disord. 2019 Dec 9;39:101891. doi: 10.1016/j.msard.2019.101891. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Epidemiology
Crouse DL, Foroughi I, Gupta N.
Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985. [Epub ahead of print]
Summary(link is external)
Other
Ghaderi S, Berg-Hansen P, Bakken IJ, Magnus P, Trogstad L, Håberg SE.
Hospitalization following influenza infection and pandemic vaccination in multiple sclerosis patients: a nationwide population-based registry study from Norway.
Eur J Epidemiol. 2019 Dec 23. doi: 10.1007/s10654-019-00595-2. [Epub ahead of print]
Summary(link is external)
Ehling R, Amprosi M, Kremmel B, Bsteh G, Eberharter K, Zehentner M, Steiger R, Tuovinen N, Gizewski ER, Benke T, Berger T, Spöttl C, Brenneis C, Scherfler C.
Second language learning induces grey matter volume increase in people with multiple sclerosis.
PLoS One. 2019 Dec 23;14(12):e0226525. doi: 10.1371/journal.pone.0226525. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Other treatments
Pfeuffer S, Rolfes L, Bormann E, Sauerland C, Ruck T, Schilling M, Melzer N, Brand M, Pul R, Kleinschnitz C, Wiendl H, Meuth SG.
Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses.
J Clin Med. 2019 Dec 22;9(1). pii: E35. doi: 10.3390/jcm9010035.
Summary(link is external)
Read the full text of this paper (link is external)
Paulo DL, Lopez AM, Jermakowicz WJ, Yu H, Shah H, Konrad PE, Englot DJ.
Microvascular Decompression for Trigeminal Neuralgia in Patients with Multiple Sclerosis: Predictors of Treatment Success.
World Neurosurg. 2019 Dec 23. pii: S1878-8750(19)33110-9. doi: 10.1016/j.wneu.2019.12.081. [Epub ahead of print]
Summary(link is external)
Dominique I, Tremblais B, Charvier K, Nogueira MCS, Paparel P, Journel NM, Ruffion A.
How long does the effect of botulinum toxin in neurogenic patients last? An analysis of the subset of "good responders".
Low Urin Tract Symptoms. 2019 Dec 19. doi: 10.1111/luts.12297. [Epub ahead of print]
Summary(link is external)
Hildebrand A, Minnier J, Cameron MH.
Cannabis use for symptom relief in multiple sclerosis: A cross-sectional survey of webinar attendees in the US and Canada.
Mult Scler Relat Disord. 2019 Nov 11;38:101516. doi: 10.1016/j.msard.2019.101516. [Epub ahead of print]
Summary(link is external)
Physical activity
Pilutti LA, Edwards T, Motl RW, Sebastião E.
Functional Electrical Stimulation Cycling Exercise in People with Multiple Sclerosis: Secondary Effects on Cognition, Symptoms, and Quality of Life.
Int J MS Care. 2019 Nov-Dec;21(6):258-264. doi: 10.7224/1537-2073.2018-048.
Summary(link is external)
Read the full text of this paper (link is external)
Tollár J, Nagy F, Tóth BE, Török K, Szita K, Csutorás B, Moizs M, Hortobágyi T.
Exercise Effects on Multiple Sclerosis Quality of Life and Clinical-Motor Symptoms.
Med Sci Sports Exerc. 2019 Dec 23. doi: 10.1249/MSS.0000000000002228. [Epub ahead of print]
Summary(link is external)
Pregnancy and childbirth
Burkill S, Vattulainen P, Geissbuehler Y, Sabido Espin M, Popescu C, Suzart-Woischnik K, Hillert J, Artama M, Verkkoniemi-Ahola A, Myhr KM, Cnattingius S, Korhonen P, Montgomery S, Bahmanyar S.
The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.
PLoS One. 2019 Dec 30;14(12):e0227120. doi: 10.1371/journal.pone.0227120. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Smith AL, Cohen JA, Ontaneda D, Rensel M.
Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero.
Mult Scler J Exp Transl Clin. 2019 Dec 12;5(4):2055217319891744. doi: 10.1177/2055217319891744. eCollection 2019 Oct-Dec.
Summary(link is external)
Read the full text of this paper (link is external)
Prognosis
Bsteh G, Hegen H, Dosser C, Auer M, Berek K, Wurth S, Zinganell A, Di Pauli F, Deisenhammer F, Berger T.
To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.
Mult Scler Relat Disord. 2019 Dec 23;39:101908. doi: 10.1016/j.msard.2019.101908. [Epub ahead of print]
Summary(link is external)
Lorefice L, Destro F, Fenu G, Mallus M, Gessa I, Sechi V, Barracciu MA, Frau J, Coghe G, Carmagnini D, Marrosu MG, Saba L, Cocco E.
The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis.
Mult Scler Relat Disord. 2019 Dec 9;39:101886. doi: 10.1016/j.msard.2019.101886. [Epub ahead of print]
Summary(link is external)
Ziemssen T, Tolley C, Bennett B, Kilgariff S, Jones E, Pike J, Tomic D, Piani-Meier D, Lahoz R.
A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
Mult Scler Relat Disord. 2019 Nov 18;38:101861. doi: 10.1016/j.msard.2019.101861. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Psychological aspects
Walker LAS, Gardner C, Freedman MS, MacLean H, Rush C, Bowman M.
Research-to-Practice Gaps in Multiple Sclerosis Care for Patients with Subjective Cognitive, Mental Health, and Psychosocial Concerns in a Canadian Center.
Int J MS Care. 2019 Nov-Dec;21(6):243-248. doi: 10.7224/1537-2073.2017-090.
Summary(link is external)
Read the full text of this paper (link is external)
Bassi M, Grobberio M, Negri L, Cilia S, Minacapelli E, Niccolai C, Pattini M, Pietrolongo E, Quartuccio ME, Viterbo RG, Allegri B, Amato MP, Benin M, De Luca G, Falautano M, Gasperini C, Patti F, Trojano M, Delle Fave A.
The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis.
J Clin Psychol Med Settings. 2019 Dec 23. doi: 10.1007/s10880-019-09692-6. [Epub ahead of print]
Summary(link is external)
Dorstyn DS, Mathias JL, Bombardier CH, Osborn AJ.
Motivational interviewing to promote health outcomes and behaviour change in multiple sclerosis: a systematic review.
Clin Rehabil. 2020 Mar;34(3):299-309. doi: 10.1177/0269215519895790. Epub 2019 Dec 23.
Summary(link is external)
Swanepoel I, van Staden W, Fletcher L.
Psychological Resilience and Vulnerability as Mediators Between Adverse Life Events and Fatigue, Motor Dysfunction, and Paresthesia in Multiple Sclerosis.
Psychosom Med. 2020 Feb/Mar;82(2):138-146. doi: 10.1097/PSY.0000000000000770.
Summary(link is external)
Rehabilitation
Lahelle AF, Øberg GK, Normann B.
Group dynamics in a group-based, individualized physiotherapy intervention for people with multiple sclerosis: A qualitative study.
Physiother Res Int. 2019 Dec 27:e1829. doi: 10.1002/pri.1829. [Epub ahead of print]
Summary(link is external)
Relapses
Scott TF, Diehl D, Elmalik W, Gettings EJ, Hackett C, Schramke CJ.
Multiple sclerosis relapses contribute to long-term disability.
Acta Neurol Scand. 2019 Nov;140(5):336-341. doi: 10.1111/ane.13149. Epub 2019 Aug 8.
Summary(link is external)
Self-management
Babbage DR, van Kessel K, Drown J, Thomas S, Sezier A, Thomas P, Kersten P.
MS Energize: Field trial of an app for self-management of fatigue for people with multiple sclerosis.
Internet Interv. 2019 Nov 9;18:100291. doi: 10.1016/j.invent.2019.100291. eCollection 2019 Dec.
Summary(link is external)
Read the full text of this paper (link is external)
Wendrich K, van Oirschot P, Martens MB, Heerings M, Jongen PJ, Krabbenborg L.
Toward Digital Self-monitoring of Multiple Sclerosis: Investigating First Experiences, Needs, and Wishes of People with MS.
Int J MS Care. 2019 Nov-Dec;21(6):282-291. doi: 10.7224/1537-2073.2018-083.
Summary(link is external)
Read the full text of this paper (link is external)
Symptoms and symptom management
Hersche R, Weise A, Michel G, Kesselring J, Barbero M, Kool J.
Development and Preliminary Evaluation of a 3-Week Inpatient Energy Management Education Program for People with Multiple Sclerosis-Related Fatigue.
Int J MS Care. 2019 Nov-Dec;21(6):265-274. doi: 10.7224/1537-2073.2018-058.
Summary(link is external)
Read the full text of this paper (link is external)
El-Wahsh S, Ballard K, Kumfor F, Bogaardt H.
Prevalence of self-reported language impairment in multiple sclerosis and the association with health-related quality of life: An international survey study.
Mult Scler Relat Disord. 2019 Dec 16;39:101896. doi: 10.1016/j.msard.2019.101896. [Epub ahead of print]
Summary(link is external)
Solaro C, Cuccaro A, Gamberini G, Patti F, D'Amico E, Bergamaschi R, Berra E, Giusti A, Rezzani C, Messmer Uccelli M, Grasso MG.
Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy.
Neurol Sci. 2019 Dec 20. doi: 10.1007/s10072-019-04198-3. [Epub ahead of print]
Summary(link is external)


Updated NICE multiple sclerosis guideline contains some good news and some bad news
22/06/2022 - 00:00
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.


The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.


Is a ketogenic diet good for people with multiple sclerosis?
18/05/2022 - 00:00
Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.

Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.